Fidelis Capital Partners LLC Invests $205,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Fidelis Capital Partners LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,525 shares of the biopharmaceutical company’s stock, valued at approximately $205,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. PCA Investment Advisory Services Inc. purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $25,000. OFI Invest Asset Management acquired a new stake in shares of Gilead Sciences during the third quarter worth $26,000. Tompkins Financial Corp grew its holdings in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares during the last quarter. Fortitude Family Office LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $29,000. Finally, Rakuten Securities Inc. purchased a new position in Gilead Sciences in the 4th quarter worth $33,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Barclays cut their price objective on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a report on Monday, February 12th. Cantor Fitzgerald reduced their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. Wells Fargo & Company dropped their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. Mizuho reduced their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 price target on shares of Gilead Sciences in a report on Friday. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $84.71.

Gilead Sciences Stock Up 0.9 %

Shares of GILD opened at $66.76 on Friday. The firm has a market cap of $83.12 billion, a P/E ratio of 14.84, a PEG ratio of 0.92 and a beta of 0.19. Gilead Sciences, Inc. has a 12 month low of $65.90 and a 12 month high of $87.86. The stock’s 50 day moving average is $71.96 and its two-hundred day moving average is $76.56. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The company had revenue of $7.12 billion during the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. Gilead Sciences’s revenue was down 3.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.67 EPS. Analysts predict that Gilead Sciences, Inc. will post 6.55 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 4.61%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s payout ratio is presently 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.